Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q1 2023 call → NOWe need to determine if management's forward account is substantially about narrating what its counterparties are doing and scaling, such that the company's own coming volume is presented as a consequence of those parties' trajectories. The transcript covers Sun Life's Q1 2023 earnings call. Management discusses various business segments: MFS, SLC Management, Canada, U.S., Asia. They talk about sales, growth, partnerships, etc. The question asks specifically about counterparties—customers, partners, licensees, etc. that the company already supplies or serves, and whether management's forward account is about those counterparties' own growth. Looking at the transcript, management mentions several partnerships and initiatives. For example, in the U.S., they mention partnerships with AbleTo and GoodPath for mental health services, and Sun Life Health Navigator powered by Pinnacle Care. They describe how these services help members. But these are more about the company's offerings to its members, not about the counterparties' own expansion. They also mention DentaQuest, which is an acquisition, and they talk about winning new business, Medicaid and commercial wins. They say "These contract awards, along with other dental sales in the quarter will allow us to improve preventative care and oral health outcomes for an additional 650,000 members as they are onboarded over the next year." That is about the company's own wins, not about the counterparties' trajectories. They also mention a Bancassurance partnership in Hong Kong with Dawson Bank, where Sun Life will be exclusive provider to Dawson Bank's 570,000 retail banking customers. That is a partnership, but the description is about the opportunity, not about Dawson Bank's own expansion. They say "We remain excited about the opportunity to further our growth in Asia as markets are open following pandemic restrictions and will leverage our quality distribution channels." That is more about market conditions.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.